Initial characteristics of the 500 adult patients with HL at CS IA and IIA included in the H81 and H90 trials
. | Group A . | Group B . | Group C . |
---|---|---|---|
No. of patients | 42 | 144 | 314 |
No. male/no. female (ratio) | 31/11 (2.8) | 103/41 (2.5) | 122/192 (0.6) |
Age | |||
Below 40 y, no. | 30 | 90 | 255 |
At least 40 y, no. | 12 | 54 | 59 |
Site of initial node | |||
Upper cervical, no. | 19 | 70 | 16 |
Axillary/epitrochlear, no. | 9 | 11 | 5 |
Inguinal/pelvic, no. | 11 | 18 | 0 |
Supraclavicular, no. | 3 | 45 | 228 |
Mediastinal, no. | 0 | 0 | 65 |
Clinical stages | |||
Peripheral IA, no. | 21 | 68 | 0 |
Other IA, no. | 3 | 22 | 25 |
IIA, no. | 18 | 54 | 289 |
Hemoglobin level, g/dL* | 14.4 ± 0.2 | 14.1 ± 0.1 | 13.1 ± 0.1 |
Leukocytes, × 109/L* | 7.0 ± 0.3 | 8.3 ± 0.3 | 10.4 ± 0.2 |
Lymphocytes, × 109/L* | 2.1 ± 0.1 | 1.9 ± 0.7 | 1.7 ± 0.4 |
Platelets, × 109/L* | 256.1 ± 1.1 | 305.9 ± 7.2 | 355.5 ± 6.4 |
Sedimentation rate, mm/h* | 9 ± 1 | 17 ± 1 | 34 ± 1 |
. | Group A . | Group B . | Group C . |
---|---|---|---|
No. of patients | 42 | 144 | 314 |
No. male/no. female (ratio) | 31/11 (2.8) | 103/41 (2.5) | 122/192 (0.6) |
Age | |||
Below 40 y, no. | 30 | 90 | 255 |
At least 40 y, no. | 12 | 54 | 59 |
Site of initial node | |||
Upper cervical, no. | 19 | 70 | 16 |
Axillary/epitrochlear, no. | 9 | 11 | 5 |
Inguinal/pelvic, no. | 11 | 18 | 0 |
Supraclavicular, no. | 3 | 45 | 228 |
Mediastinal, no. | 0 | 0 | 65 |
Clinical stages | |||
Peripheral IA, no. | 21 | 68 | 0 |
Other IA, no. | 3 | 22 | 25 |
IIA, no. | 18 | 54 | 289 |
Hemoglobin level, g/dL* | 14.4 ± 0.2 | 14.1 ± 0.1 | 13.1 ± 0.1 |
Leukocytes, × 109/L* | 7.0 ± 0.3 | 8.3 ± 0.3 | 10.4 ± 0.2 |
Lymphocytes, × 109/L* | 2.1 ± 0.1 | 1.9 ± 0.7 | 1.7 ± 0.4 |
Platelets, × 109/L* | 256.1 ± 1.1 | 305.9 ± 7.2 | 355.5 ± 6.4 |
Sedimentation rate, mm/h* | 9 ± 1 | 17 ± 1 | 34 ± 1 |
Group A includes patients with LPHL; group B, patients with cHL without MI; and group C, patients with cHL with MI.
Data are mean ± SEM.